Asset / Drug

Trial Update

Drug and asset intelligence for Trial Update with 92 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 0
Catalysts: 92
Stage: Development stage unavailable

Sponsor company

AstraZeneca →

Recent signals

No signals indexed for this entity yet.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(92)

Topline Data

— Trial Update

Monitor trial outcomes and any subsequent changes in treatment guidelines or new product launches based on genetic testing results.

June 21, 2026 · N/A

Topline Data

— Trial Update

Results from this study could influence future research directions and regulatory policies regarding e-cigarettes.

June 21, 2026 · N/A

Topline Data

— Trial Update

Monitor the trial results for efficacy in reducing hypoxemia and subsequent adoption in clinical practice.

June 21, 2026 · N/A

Topline Data

— Trial Update

Key endpoints include new-onset hypertension, diabetes, and composite cardiovascular events; results will be pivotal for future treatment protocols.

June 21, 2026 · N/A

Topline Data

Pacira Pharmaceuticals — Trial Update

Monitor trial results and participant outcomes over the 14-month study period for potential shifts in clinical practice.

June 21, 2026 · N/A

Topline Data

— Trial Update

Monitor results for potential biomarkers that could be leveraged in future PTSD treatment protocols.

June 21, 2026 · N/A

Topline Data

— Trial Update

Monitor results from this study for insights into the relationship between MRI findings and cognitive outcomes in preterm infants.

June 21, 2026 · N/A

Topline Data

— Trial Update

Monitor results from the trial, particularly the efficacy of the probiotic mixture compared to placebo and any changes in cachexia-related measures.

June 21, 2026 · N/A

Topline Data

— Trial Update

Monitor results from this study for insights into sleep interventions and their effects on cardiovascular outcomes in type 1 diabetes.

June 21, 2026 · N/A

Topline Data

— Trial Update

Monitor study results and any subsequent changes in treatment guidelines or competitive responses from other epilepsy drug developers.

June 21, 2026 · N/A

Topline Data

— Trial Update

Monitor results from the Dulce Digital 2.0 study for insights on the effectiveness of digital interventions in diabetes self-management.

June 21, 2026 · N/A

Topline Data

— Trial Update

Monitor results and findings from the study for potential shifts in rehabilitation practices.

June 21, 2026 · N/A

Topline Data

— Trial Update

Monitor results on hs-CRP levels and glycemic outcomes post-intervention, as well as any subsequent changes in dietary recommendations for diabetes.

June 21, 2026 · N/A

Topline Data

— Trial Update

Monitor the trial outcomes related to hormonal and metabolic parameters, as well as quality of life improvements.

June 21, 2026 · N/A

Topline Data

— Trial Update

Monitor ongoing vaccination rates and subsequent trends in high-grade CIN consultations in Brazil and other regions adopting similar vaccination programs.

June 20, 2026 · N/A

Topline Data

— Trial Update

Monitor trial results and any announcements regarding efficacy compared to everolimus.

June 20, 2026 · N/A

Topline Data

AbbVie — Trial Update

Key milestones include dose escalation results and interim efficacy data over the 6-year study duration.

June 20, 2026 · N/A

Topline Data

Roche — Trial Update

Key milestones include interim results and final efficacy data from the trial, as well as any regulatory discussions that may arise.

June 20, 2026 · N/A

Topline Data

— Trial Update

Monitor trial results and adherence metrics, as well as any subsequent adoption of the CONCURxP platform in clinical practice.

June 20, 2026 · N/A

Topline Data

— Trial Update

Monitor results from neuropsychological tests and quality of life assessments post-treatment at follow-up visits.

June 20, 2026 · N/A

Topline Data

— Trial Update

Monitor results and publications from this study for insights into cancer-related fatigue management.

June 20, 2026 · N/A

Topline Data

— Trial Update

Monitor for study results and any emerging data on vaccine safety in this patient cohort.

June 20, 2026 · N/A

Topline Data

— Trial Update

Monitor enrollment progress, interim results on malnutrition rates, and cost-effectiveness findings.

June 20, 2026 · N/A

Topline Data

— Trial Update

Monitor the study's progress and results regarding safety and effectiveness, as well as its impact on hospitalization rates.

June 20, 2026 · N/A

Topline Data

— Trial Update

Monitor the trial's progress, particularly the outcomes related to self-care and hospitalization rates, as well as the adoption of the digital health application.

June 20, 2026 · N/A

Topline Data

Lilly — Trial Update

Monitor results of the study for potential new biomarkers and their implications for treatment protocols in ITP.

June 20, 2026 · N/A

Topline Data

— Trial Update

Monitor trial results for efficacy in reducing delayed neurocognitive recovery and subsequent adoption in clinical practice.

June 20, 2026 · N/A

Topline Data

AstraZeneca — Trial Update

Monitor ongoing trials assessing the combination of NK-cell immunotherapy and thermal ablation in HCC.

June 20, 2026 · N/A

Topline Data

AstraZeneca — Trial Update

Monitor further validation studies and the integration of microbiome analysis in clinical trials for immunotherapy in melanoma.

June 19, 2026 · N/A

Topline Data

— Trial Update

Monitor enrollment progress, interim results, and overall survival data from the trial as key indicators of treatment efficacy.

June 19, 2026 · N/A

Topline Data

— Trial Update

Monitor results from the trial for potential breakthroughs in understanding MORC2-related disorders and implications for treatment.

June 19, 2026 · N/A

Topline Data

— Trial Update

Results from sample analyses and any emerging genetic insights that could inform future drug development.

June 19, 2026 · N/A

Topline Data

— Trial Update

Results from genetic analyses and any emerging correlations with hearing loss treatments or diagnostics.

June 19, 2026 · N/A

Topline Data

— Trial Update

Monitor trial results and any subsequent changes in rehabilitation protocols or new product developments in stroke care.

June 19, 2026 · N/A

Topline Data

— Trial Update

Monitor study results for insights on cardiovascular risks in ADHD patients and any emerging treatment guidelines.

June 19, 2026 · N/A

Topline Data

— Trial Update

Key results from genomic testing and participant feedback on treatment management will be critical to follow.

June 19, 2026 · N/A

Topline Data

— Trial Update

Monitor results from the trial for efficacy data and the establishment of standard operating procedures.

June 19, 2026 · N/A

Topline Data

AstraZeneca — Trial Update

Monitor the study's progress and results, particularly regarding treatment access and patient demographics, which could influence future therapeutic strategies.

June 19, 2026 · N/A

Topline Data

— Trial Update

Monitor results related to weight loss efficacy and metabolic changes, particularly hepatic de novo lipogenesis and beta cell recovery.

June 19, 2026 · N/A

Topline Data

— Trial Update

Key milestones include interim results on tumor growth rates and genetic findings over the 24-month follow-up period.

June 19, 2026 · N/A

Topline Data

— Trial Update

Monitor results of the study for prevalence data and implications for patient management.

June 19, 2026 · N/A

Topline Data

— Trial Update

Monitor the study's outcomes on blood vessel health, mood, and quality of life metrics, as well as any subsequent publications.

June 19, 2026 · N/A

Topline Data

— Trial Update

Monitor findings from the study regarding frailty indicators and their correlation with chronic health conditions in survivors.

June 18, 2026 · N/A

Topline Data

— Trial Update

Monitor the trial results for 1-year all-cause mortality and readmission rates, as well as any subsequent publications or regulatory filings.

June 18, 2026 · N/A

Topline Data

Pfizer — Trial Update

Monitor trial results for efficacy and safety, particularly the selection of the optimal dosing regimen.

June 18, 2026 · N/A

Topline Data

— Trial Update

Monitor outcomes and findings from this protocol that could influence treatment standards and patient management in pediatric oncology.

June 18, 2026 · N/A

Topline Data

— Trial Update

Monitor trial results and patient outcomes, particularly regarding safety and efficacy of the combined treatment approach.

June 18, 2026 · N/A

Topline Data

— Trial Update

Follow trial results and any subsequent changes in clinical guidelines regarding radiation therapy in breast cancer.

June 18, 2026 · N/A

Topline Data

— Trial Update

Monitor trial results and any reported complications, as well as subsequent regulatory filings or partnerships that may arise from the study.

June 18, 2026 · N/A

Topline Data

Roche — Trial Update

Key milestones include interim results on disease progression and feasibility of photoreceptor loss as a clinical endpoint.

June 18, 2026 · N/A

Topline Data

— Trial Update

Monitor trial results for improvements in LVEF and NYHA classifications, as well as any changes in clinical practice guidelines following the study's outcomes.

June 18, 2026 · N/A

Topline Data

— Trial Update

Monitor outcomes related to hospital stays, complications, and readmissions as the study progresses.

June 18, 2026 · N/A

Topline Data

Novartis — Trial Update

Monitor recruitment progress and results from the feasibility phase, as well as the design of the larger follow-up study.

June 18, 2026 · N/A

Topline Data

— Trial Update

Monitor trial results and any announcements regarding interim analyses or regulatory submissions.

June 17, 2026 · N/A

Topline Data

GSK — Trial Update

Monitor trial results and any subsequent regulatory actions or changes in treatment recommendations.

June 17, 2026 · N/A

Topline Data

Moderna — Trial Update

Monitor further trial results and regulatory developments for mRNA-1083, especially regarding its approval and market entry.

June 17, 2026 · N/A

Topline Data

AstraZeneca — Trial Update

Monitor trial results and any subsequent publications that may reveal new insights into treatment combinations or patient outcomes.

June 17, 2026 · N/A

Topline Data

Novartis — Trial Update

Monitor results on safety, efficacy, and overall survival rates post-infusion, as well as any reports of graft-versus-host disease.

June 17, 2026 · N/A

Topline Data

— Trial Update

Monitor trial results and any subsequent regulatory filings or partnerships that may arise from this study.

June 17, 2026 · N/A

Topline Data

Pfizer — Trial Update

Monitor trial results for improvements in quality of life and health metrics, as well as adherence rates among participants.

June 17, 2026 · N/A

Topline Data

Pfizer — Trial Update

Monitor results from the trial regarding quality of life, pain, and anxiety outcomes compared to traditional self-care methods.

June 17, 2026 · N/A

Topline Data

Ganzhou Hemay Pharmaceutical Co., Ltd — Trial Update

Key milestones include interim results and final efficacy data from the trial.

June 17, 2026 · N/A

Topline Data

AstraZeneca — Trial Update

Monitor trial results for improvements in survival outcomes and any changes in treatment guidelines following the study's completion.

June 17, 2026 · N/A

Topline Data

Moderna — Trial Update

Monitor regulatory updates and real-world efficacy data as mRNA-1283 is deployed against emerging COVID-19 variants.

June 16, 2026 · N/A

Topline Data

Lilly — Trial Update

Monitor upcoming regulatory submissions and market launch strategies for Foundayo, as well as competitor responses.

June 16, 2026 · N/A

Topline Data

Lilly — Trial Update

Monitor further data releases from the ATTAIN trials and any competitive responses from other obesity treatments.

June 16, 2026 · N/A

Topline Data

Lilly — Trial Update

Monitor further trial results and regulatory submissions for retatrutide, as well as competitor responses.

June 16, 2026 · N/A

Topline Data

Roche — Trial Update

Monitor FDA feedback on giredestrant's New Drug Application and outcomes from the ASCO presentations, particularly regarding efficacy and safety across different patient populations.

June 16, 2026 · N/A

Topline Data

Roche — Trial Update

Monitor the outcomes of the lidERA and persevERA studies presented at ASCO 2026, particularly any changes in treatment guidelines.

June 16, 2026 · N/A

Topline Data

Roche — Trial Update

Monitor the outcomes of the Phase II studies and subsequent market reactions post-presentation at the ADA.

June 16, 2026 · N/A

Topline Data

Roche — Trial Update

Monitor the outcomes of the Phase II studies and subsequent market reactions following the ADA presentation.

June 16, 2026 · N/A

Topline Data

— Trial Update

Monitor trial results and any announcements regarding efficacy and safety outcomes over the 52-week period.

June 15, 2026 · N/A

Topline Data

Lilly — Trial Update

Monitor upcoming data releases and regulatory filings related to AJ1-11095, as well as competitor responses.

June 14, 2026 · N/A

Topline Data

GSK — Trial Update

Monitor for regulatory decisions and further trial phases, as well as competitive responses from other vaccine developers.

June 14, 2026 · N/A

Topline Data

— Trial Update

Monitor the study's primary endpoint results regarding complication rates and any subsequent changes in clinical guidelines for catheterization in obese patients.

June 13, 2026 · N/A

Topline Data

AstraZeneca — Trial Update

Monitor the trial's progress and results for potential shifts in treatment protocols and competitive dynamics in oncology.

June 13, 2026 · N/A

Topline Data

AstraZeneca — Trial Update

Monitor enrollment progress and initial results for efficacy and safety outcomes.

June 12, 2026 · N/A

Topline Data

— Trial Update

Follow-up on trial results and publication of findings to gauge the impact on clinical practice and market dynamics.

June 12, 2026 · N/A

Topline Data

— Trial Update

Monitor for further studies on long-term immunity and safety in diverse populations, as well as regulatory responses to these findings.

June 11, 2026 · N/A

Topline Data

— Trial Update

Monitor the trial results for changes in clinical practice guidelines and potential shifts in midazolam usage in pediatric settings.

June 11, 2026 · N/A

Topline Data

— Trial Update

Monitor results on feasibility and acceptability of Behavioral Activation, as well as any significant outcomes related to AUD/PTSD recovery.

June 11, 2026 · N/A

Topline Data

AstraZeneca — Trial Update

Monitor outcomes related to treatment efficacy and any subsequent changes in clinical practice guidelines based on study findings.

June 11, 2026 · N/A

Topline Data

— Trial Update

Monitor results on HbA1c reduction and safety outcomes, as well as plans for larger confirmatory trials based on this proof-of-concept study.

June 10, 2026 · N/A

Topline Data

Lilly — Trial Update

Monitor further trial results and regulatory developments for retatrutide, as well as competitor responses.

June 7, 2026 · N/A

Topline Data

AstraZeneca — Trial Update

Monitor regulatory submissions and potential market launch timelines following these trial results.

June 2, 2026 · N/A

Topline Data

AstraZeneca — Trial Update

Monitor further data releases from the Phase III trials and any regulatory submissions or approvals.

June 2, 2026 · N/A

Topline Data

— Trial Update

Monitor the trial results for differences in opioid consumption and respiratory outcomes, as well as subsequent adoption in clinical practice.

June 2, 2026 · N/A

Topline Data

— Trial Update

Monitor results for safety and efficacy outcomes, as well as any subsequent larger trials based on pilot findings.

June 2, 2026 · N/A

Topline Data

— Trial Update

Monitor trial results regarding recovery metrics and complication rates, expected in the next 6-12 months.

June 2, 2026 · N/A

Topline Data

AstraZeneca — Trial Update

Results from the TAPUR study and subsequent publications on the effectiveness of targeted therapies in the specified patient population.

June 2, 2026 · N/A

Topline Data

— Trial Update

Key milestones include interim results on visual acuity and safety data at the 52-week mark.

June 1, 2026 · N/A

Topline Data

AstraZeneca — Trial Update

Monitor the trial's progress, participant outcomes, and any published results regarding the efficacy of NMES in this patient population.

June 1, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Anesthesia · Monitoring →

Anesthesiology · Pediatric Surgery →

Cardiology · Cardiogenic Shock →

Cardiology · Heart Failure →

Cardiology · Microvascular Health →

Cardiology · Surgical Intervention →

Cardiovascular · Hypertension →

Critical Care · Catheterization →

Dermatology · Incontinence-Associated Dermatitis →

Diabetes · GLP-1 →

Endocrinology · Diabetes →

Endocrinology · Obesity →

Endocrinology · PCOS →

Endocrinology · Type 1 Diabetes →

Endocrinology · Type 2 Diabetes →

Gastroenterology · Ulcerative Colitis →

Genetic Disorders · Fabry Disease →

Hematology · Amyloidosis →

Hematology · Immune Thrombocytopenic Purpura →

Hematology · Myelofibrosis →

Infectious Disease · Cell Therapy →

Infectious Disease · COVID-19 →

Infectious Disease · Fungal Infections →

Infectious Disease · Influenza →

Infectious Disease · Vaccine →

Infectious Disease · Vaccines →

Mental Health · Behavioral Interventions →

Musculoskeletal · Osteoarthritis →

Neurology · ADHD →

Neurology · Charcot-Marie-Tooth Disease →

Neurology · Dysphagia →

Neurology · Neurodevelopmental Disorders →

Neurology · Pediatric Demyelinating Diseases →

Neurology · Status Epilepticus →

Neurology · Stroke →

Obesity · Endoscopic Procedure →

Obesity · Oral GLP-1 receptor agonist →

Obesity · Peptide Therapy →

Obesity · Triple Agonist →

Oncology · Brain Metastases →

Oncology · Brain Tumors →

Oncology · Breast Cancer →

Oncology · Cancer-related Fatigue →

Oncology · Cervical Cancer →

Oncology · CNS Tumors →

Oncology · Colorectal Cancer →

Oncology · Esophageal Squamous Cell Carcinoma →

Oncology · Hepatocellular Carcinoma →

Oncology · Image-Guided Therapy →

Oncology · Immunotherapy →

Oncology · Liver Cancer →

Oncology · mCRC →

Oncology · Melanoma →

Oncology · Non-Hodgkin Lymphoma →

Oncology · Oropharyngeal Cancer →

Oncology · Pediatric →

Oncology · Pediatric Cancer →

Oncology · Prostate Cancer →

Oncology · Radiation Therapy →

Oncology · Radioconjugate →

Oncology · Rectal Cancer →

Oncology · Skin Tumors →

Oncology · Supportive Care →

Oncology · Surgery →

Oncology · Surgical Care →

Oncology · Survivorship →

Oncology · Targeted Therapy →

Ophthalmology · Age-Related Macular Degeneration →

Ophthalmology · Diabetic Macular Edema →

Otolaryngology · Hearing Loss →

Pain Management · Anesthesia →

Pain Management · Chronic Low Back Pain →

Pediatrics · Malnutrition →

Psychiatry · PTSD →

Pulmonology · Obstructive Sleep Apnea →

Rare Diseases · Hypophosphatasia →

Respiratory · COPD →

Women's Health · Menopause →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.